Plain-English translation of NCT07610616 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing how well certain antibody-drug medications—particularly trastuzumab emtansine and trastuzumab deruxtecan—work against lung cancer that has specific markers called HER2 or TROP2. Researchers will grow cancer cells from your tumor tissue in the lab, add immune cells to simulate how your body would respond, and then test whether the medication can kill the cancer cells. This research aims to understand exactly how these medications work and who might benefit most from them.
Some patients with lung cancer have tumors that express HER2 or TROP2 markers, which makes them candidates for special antibody-drug treatments. However, doctors don't fully understand why these medications work better for some patients than others, or how to best combine them with other therapies. This study exists to answer those questions so that future patients can receive more personalized and effective treatment.
You likely qualify if…
You likely don't qualify if…
Your participation would involve providing tumor tissue (usually from surgery) and immune cells (from blood or fluid around the lungs) so researchers can grow your cancer in the lab and test how it responds to the medication. The research team will expose your tumor cells to the treatment and measure whether the cancer dies, how the immune cells react, and which cancer cells are most sensitive to the medication. This is laboratory-based research; you would not receive the medication as part of this study, though the results may help guide your future treatment decisions.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China